Back to results
US 12,280,061 B2Granted
Optimised dosage of diaminophenothiazines in populations
AssigneeWisTa Laboratories Ltd.
InventorsClaude Michel Wischik, Björn Olaf Schelter, Helen Christine Shiells
Life of this patent
Estimating the term…
Abstract
The invention provides novel dosing regimens for Leuco-Methylthioninium (LMT) compounds which maximise the proportion of subjects in which the MT concentration will exceed concentrations in which therapeutic efficacy in relation to treatment of neurodegenerative disorders such as Alzheimer's disease and rontotemporal dementias can be achieved, while maintaining a desirable clinical profile. Also provided are LMT-containing dosage units and other compositions.
Claims20
A method of therapeutic treatment of a neurodegenerative disorder of protein aggregation in a human subject,
- which method comprises orally administering to said subject a methylthioninium (MT)-containing compound,
- wherein said administration provides a total daily dose of between 20.5 and 60 mg of MT to the subject per day, optionally split into 2 or more doses,
- wherein the MT-containing compound is LMTM:
- and
- wherein said neurodegenerative disorder is Alzheimer's disease.
2 more elements
Dependencies are inferred from the claim text.